Long-term results of the AIEOP LNH-97 protocol for childhood lymphoblastic lymphoma

Pediatric Blood & Cancer
Marta PillonAngelo Rosolen

Abstract

Treatment intensification was considered a suitable strategy to increase the cure rate of lymphoblastic lymphoma (LBL) in children. The AIEOP LNH-97 trial was run between 1997 and 2007 for newly diagnosed LBL in patients aged less than 18 years. Treatment schedule was based on the previous, LSA2-L2 derived, AIEOP LNH-92 protocol. Modifications included: increased dose of upfront cyclophosphamide and methotrexate, use of l-Asparaginase during induction therapy, intensive block therapy for slow responders, and late intensification ("Reinduction") for patients with advanced stage disease. Total therapy duration was 12 months for stage I and II, and 24 months for stage III and IV. Central nervous system prophylaxis did not include cranial irradiation. 114 eligible patients were enrolled, 84 males and 30 females; median age was 9 years. Complete remission was obtained in 98% of patients. After a median follow-up time of seven years, 29 patients failed due to progression of disease (n = 2), relapse (n = 25), or second malignancy (n = 2). The 7-year overall survival was 82% (standard error [SE] 4%) and the 7-year event-free survival was 74% (SE 4%). No subgroup showed significantly different event free survival. None of the patients d...Continue Reading

References

Jun 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D G TubergenJ H Kersey
Feb 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A ReiterH Riehm
Jun 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J R AndersonA T Meadows
Nov 29, 2002·Blood·John E LevineUNKNOWN Lymphoma Study Writing Committee, International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant R
Jan 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Birgit BurkhardtAlfred Reiter
Mar 18, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Anne UyttebroeckUNKNOWN Children's Leukaemia Group (CLG) of the European Organisation for Research and Treatment of Cancer (EORTC)
Jun 24, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elaine Coustan-SmithDario Campana
Oct 6, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Thomas G GrossMary Eapen
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Celine CallensElizabeth Macintyre
Jun 22, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J T SandlundR C Ribeiro
Nov 19, 2013·Pediatric Blood & Cancer·Yi-Jin GaoJian-Hua Meng

❮ Previous
Next ❯

Citations

Mar 19, 2016·British Journal of Haematology·Birgit BurkhardtSherrie L Perkins
May 3, 2016·British Journal of Haematology·Mitchell S Cairo, Ross Pinkerton
Jun 25, 2016·Journal of the Egyptian National Cancer Institute·Hany Abdel Rahman SayedDina Hesham
Oct 25, 2016·European Journal of Medical Genetics·Valentina DecimiAngelo Selicorni
Dec 21, 2018·American Journal of Medical Genetics. Part a·Emmanuel de BillyFranco Locatelli
May 13, 2020·Leukemia·Andishe AttarbaschiUNKNOWN European Intergroup for Childhood Non-Hodgkin’s Lymphoma (EICNHL) and the International Berlin-Frankfurt-Münster (i-BFM) Stu
Jun 20, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J HayashiCatherine M Bollard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

© 2022 Meta ULC. All rights reserved